Description
TC 250 – Testosterone Cypionate 250mg/ml
TC 250 is a long-acting injectable solution containing testosterone cypionate at a concentration of 250mg/ml. Recognized for its extended half-life of approximately 8 days, this ester ensures stable plasma testosterone levels with reduced injection frequency, making it an optimal choice for foundational hormone support in performance-enhancement protocols.
Clinically utilized for testosterone replacement therapy, TC 250 is widely adopted in athletic contexts to promote lean muscle mass development, enhance strength, support recovery, and improve red blood cell production. Its gradual release profile allows for more controlled hormonal dynamics compared to faster esters.
Application:
TC 250 is commonly incorporated into muscle-building phases, either as a standalone compound or in combination with agents such as Nandrolone Decanoate (Deca 300) or Boldenone Undecylenate (Boldenon 300) to promote synergistic anabolic effects.
Important Note:
Testosterone cypionate suppresses natural testosterone production. Proper post-cycle therapy (PCT) is recommended to support endocrine recovery following use.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.